Skip to content
Subscriber Only

Glaxo and Sanofi Are Discussing $620 Million U.K. Vaccine Deal

  • Partners discuss vaccine supply with different countries
  • Glaxo, Sanofi plan to begin tests in humans in September
Inside GSK’s Research And Development Center
Photographer: Simon Dawson/Bloomberg

GlaxoSmithKline Plc and Sanofi, partners developing a potential coronavirus vaccine, are discussing a 500 million pound ($620 million) deal to supply the U.K. government with the shot, assuming it’s successful, said a person familiar with the matter.

The companies plan to supply Britain with 60 million doses of the vaccine, which is under development, according to the person, who asked not to be identified because the details are still being finalized. The pending accord was first reported by the Sunday Times.